list glp 1 receptor agonist Classification of currently available glucagon-like peptide-1 List of approved and pending

doi: 10.1080/15548627.2021.1938914 50 YangJLZhangCPLiLHuangLJiSYLuCLet al

A., Naderi G

Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA

doi: 10.3389/fimmu.2025.1610368 Received 11 April 2025 Accepted 26 June 2025 Published 15 July 2025 Volume 16 - 2025 Edited by Li-Tung Huang, Kaohsiung Chang Gung Memorial Hospital, Taiwan Reviewed by Beata Kasztelan-Szczerbinska, Medical University of Lublin, Poland Edit Posta, University of Debrecen, Hungary Updates Copyright 2025 Migliorisi, Gabbiadini, Dal Buono, Ferraris, Privitera, Petronio, Bertoli, Bezzio and Armuzzi

Further population-based studies may quantify incidence rates, characterize dose-dependent relationships, and investigate mechanistic pathways to optimize risk stratification and therapeutic decision-making

"In combination with diet and exercise, Wegovy is the only obesity medicine proven to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight